Ricevi le ultime notizie sulle azioni Agios Pharmaceuticals con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di AGIO

Ultime notizie per

Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. - Common Stock

Panoramica

Notizie

Utili

Opzioni

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Commerci governativi

Rapporto azionario

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Comments

Agios Pharmaceuticals Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO